Parmenides z Elei, V wiek p.n.e.
tytuł oryg.: Regional abdominal hyperthermia combined with systemic chemotherapy for the treatment of patients with ovarian cancer relapse: Results of a pilot study
Wydawnictwo: International Journal of Hyperthermia
Autor główny: Jalid Sehouli
Pozostali autorzy: Christina Fotopoulou, Chie Hee Cho, Robert Kraetschell, Johanna Gellermann, Peter Wust, Werner Lichtenegger
Język publikacji: angielski
Klasa publikacji: Badanie pilotażowe
Rodzaj badania: Prospektywne, 1/2 fazy
Liczba pacjentów: 36
Rodzaj HT: LRHT RF
Rodzaj HT opis: HT miejscowa, głęboka, fale radiowe
Jednostka chorobowa: Rak jajnika wznowa
Symbol Jednostki chorobowej: OCR
Typ skojarzenia HT stosowany w badaniu: HT+CT
Rodzaj CT: Pegylated liposomal doxorubicin, Topotecane, Treosulfan, Paclitaxel/docetaxel, Gemcitabine, Cyclophosphamide, Carboplatin, Carboplatinum-based combination, Platinum sensitive, Platinum resistant
Abstract. Purpose: Due to the poor prognosis of patients with ovarian cancer relapse (OCR), newer strategies are warranted to improve the therapeutic index. We performed a prospective phase I/II-study of regional abdominal hyperthermia (RHT) combined with systemic chemotherapy in OCR patients in order to evaluate outcome, efficacy and tolerance.
Materials and methods: OCR patients with an Eastern Cooperative Oncology Group status <2, without any thromboembolic disease or severe cardiovascular co-morbidities, and pre-treated with at least one systemic chemotherapy regimen due to epithelial ovarian cancer were enrolled into the present study. RHT was applied using a SIGMA 60 applicator and a Hybrid-System SIGMA-Eye/MRT composed of a 1.5T-MRT and a Sigma-Eye-applicator.
Results: Overall, 36 OCR patients were enrolled. The majority of the patients (480%) were classified as platinum resistant. The most common chemotherapeutic agent applied was pegylated-liposomal-doxorubicin (47.2%) followed by carboplatin (16.6%) and topotecan (13.9%). One patient (2.8%) achieved a complete remission (CR), 12 patients (33.3%) yielded a partial remission (PR) and 16 patients (44.4%) developed a progressive disease (PD). In platinum-sensitive patients we observed higher response (57.1% versus 31%) and lower progression rates (28.6% versus 48.3%) than in platinum-resistant patients. Eleven patients (30.5%) discontinued treatment due to toxicity. The main toxicity was a haematological one with grade 3/4 anaemia, leucopenia and thrombocytopenia occurring in 13.9%, 5.6% and 8.3%, respectively. Median overall survival was 12 months (range: 1–48), while median progression-free survival was 5 months (range: 0.5–34).
Conclusions: Our results demonstrate the feasibility of RHT combined with systemic treatment. Prospective phase III trials are warranted to evaluate the benefit and efficacy in heavily pre-treated patients with OCR.
Potrzebujesz więcej danych o artykule? Skontaktuj się z PTHO droga mailową.